Table 3 Treatment-emergent adverse events related to TDF/FTC (none of these events were Grade 3 or 4)
n | % | |
|---|---|---|
Number of patients experiencing any adverse event related to TDF/FTC | 7 | 13% |
Cardiac disorder (palpitation) | 1 | 2% |
Gastrointestinal disorders (flatulence, faeces | ||
discoloured) | 2 | 4% |
Drug Hypersensitivity | 1 | 2% |
Increased Amylase | 1 | 2% |
Increased Creatine phosphokinase | 1 | 2% |
Lactic Acid increased | 1 | 2% |
Increased Lipase | 1 | 2% |
Arthralgia | 1 | 2% |
Nervous System Disorders (Dizziness, paraesthesia) | 1 | 2% |
Renal pain | 1 | 2% |
Rash | 1 | 2% |